Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03589469 · FLOW

Participant flow

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma · Source last updated 2023-08-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Participants received loncastuximab tesirine as an intravenous (IV) infusion over 30 minutes on Day 1 of each cycle (every 3 weeks) at a dose of 150 μg/kg once every 3 weeks (Q3W) for 2 cycles, then 75 μg/kg Q3W for subsequent cycles for up to one year or until disease progression, unacceptable toxicity, or other discontinuation criteria, whichever occurred first.
    id
    FG000
    title
    Loncastuximab Tesirine
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        8
      type
      Withdrawal by Subject
    2. reasons
      1. group Id
        FG000
        num Subjects
        20
      type
      Physician Decision
    3. reasons
      1. group Id
        FG000
        num Subjects
        97
      type
      Death
    4. reasons
      1. group Id
        FG000
        num Subjects
        8
      type
      Lost to Follow-up
    5. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Miscellaneous
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        145
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        145
      type
      Participants Received Treatment
    3. achievements
      1. group Id
        FG000
        num Subjects
        11
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        134
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Participants were enrolled at 28 study sites in Italy, Switzerland, the United Kingdom, and the United States from 01 August 2018 to 09 August 2022.
Complete source fields
groups
  1. description
    Participants received loncastuximab tesirine as an intravenous (IV) infusion over 30 minutes on Day 1 of each cycle (every 3 weeks) at a dose of 150 μg/kg once every 3 weeks (Q3W) for 2 cycles, then 75 μg/kg Q3W for subsequent cycles for up to one year or until disease progression, unacceptable toxicity, or other discontinuation criteria, whichever occurred first.
    id
    FG000
    title
    Loncastuximab Tesirine
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        8
      type
      Withdrawal by Subject
    2. reasons
      1. group Id
        FG000
        num Subjects
        20
      type
      Physician Decision
    3. reasons
      1. group Id
        FG000
        num Subjects
        97
      type
      Death
    4. reasons
      1. group Id
        FG000
        num Subjects
        8
      type
      Lost to Follow-up
    5. reasons
      1. group Id
        FG000
        num Subjects
        1
      type
      Miscellaneous
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        145
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        145
      type
      Participants Received Treatment
    3. achievements
      1. group Id
        FG000
        num Subjects
        11
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        134
      type
      NOT COMPLETED
    title
    Overall Study
recruitment Details
Participants were enrolled at 28 study sites in Italy, Switzerland, the United Kingdom, and the United States from 01 August 2018 to 09 August 2022.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice